High-Intensity Interval Training, Caloric Restriction, or Their Combination Have Beneficial Effects on Metabolically Acquired Peripheral Neuropathy
- PMID: 39163551
- PMCID: PMC11493763
- DOI: 10.2337/db23-0997
High-Intensity Interval Training, Caloric Restriction, or Their Combination Have Beneficial Effects on Metabolically Acquired Peripheral Neuropathy
Abstract
Peripheral neuropathy (PN) is a prevalent and debilitating complication of obesity, prediabetes, and type 2 diabetes, which remains poorly understood and lacks disease-modifying therapies. Fortunately, diet and/or exercise have emerged as effective treatment strategies for PN. Here, we examined the impact of caloric restriction (CR) and high-intensity interval training (HIIT) interventions, alone or combined (HIIT-CR), on metabolic and PN outcomes in high-fat diet (HFD) mice. HFD feeding alone resulted in obesity, impaired glucose tolerance, and PN. Peripheral nerves isolated from these mice also developed insulin resistance (IR). CR and HIIT-CR, but not HIIT alone, improved HFD-induced metabolic dysfunction. However, all interventions improved PN to similar extents. When examining the underlying neuroprotective mechanisms in whole nerves, we found that CR and HIIT-CR activate the fuel-sensing enzyme AMPK. We then performed complimentary in vitro work in Schwann cells, the glia of peripheral nerves. Treating primary Schwann cells with the saturated fatty acid palmitate to mimic prediabetic conditions caused IR, which was reversed by the AMPK activator, AICAR. Together, these results enhance our understanding of PN pathogenesis, the differential mechanisms by which diet and exercise may improve PN, and Schwann cell-specific contributions to nerve insulin signaling and PN progression.
© 2024 by the American Diabetes Association.
Conflict of interest statement
References
MeSH terms
Grants and funding
- N/A/Robert and Katherine Jacobs Environmental Health Initiative
- N/A/Sinai Medical Staff Foundation
- K01DK135799/NH/NIH HHS/United States
- R24 DK082841/DK/NIDDK NIH HHS/United States
- K99 DK119366/DK/NIDDK NIH HHS/United States
- NNF14OC0011633/Novo Nordisk Foundation
- N/A/NeuroNetwork for Emerging Therapies at the University of Michigan
- P30 DK020572/DK/NIDDK NIH HHS/United States
- P30 DK092926/DK/NIDDK NIH HHS/United States
- N/A/Edith S. Bristin/SKS Foundation NeuroNetwork Emerging Scholar Fund
- U2C DK135066/DK/NIDDK NIH HHS/United States
- N/A/Tauber Family Student Internship Program
- N/A/Andrea and Lawrence Wolfe Brain Health Initiative
- K01 DK135799/DK/NIDDK NIH HHS/United States
- N/A/Nathan and Rose Milstein Research Fund
- R01 DK130913/DK/NIDDK NIH HHS/United States
- R00 DK119366/DK/NIDDK NIH HHS/United States
- K99 AG071667/AG/NIA NIH HHS/United States
- N/A/Dr. John H. Doran Neuropathy Research Fund
- R00 AG071667/AG/NIA NIH HHS/United States
- U2CDK110768/DK/NIDDK NIH HHS/United States
- U2C DK110768/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources